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Clinical practices of the management of nonvalvular atrial
fibrillation and outcome of treatment: A representative
prospective survey in tertiary healthcare centers across Turkey
Non-valvüler atriyum fibrilasyonu yönetiminde klinik uygulamalar ve tedavi 
sonuçları: Türkiye genelindeki üçüncü basamak sağlık merkezlerinde yapılan ileriye 
dönük anket çalışması
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Objective: The goal of this study was to define clinical prac-
tice patterns for assessing stroke and bleeding risks and 
thromboprophylaxis in nonvalvular atrial fibrillation (NVAF) 
and to evaluate treatment outcomes and patient quality of life.
Methods: A clinical surveillance study was conducted in 10 
tertiary healthcare centers across Turkey. Therapeutic ap-
proaches and persistence with initial treatment were recorded 
at baseline, the 6th month, and the 12th month in NVAF patients.
Results: Of 210 patients (57.1% male; mean age: 64.86±12.87 
years), follow-up data were collected for 146 patients through 
phone interviews at the 6th month and 140 patients at the 12th 
month. At baseline, most patients had high CHADS2 score 
(≥2: 48.3%) and CHA2DS2-VASc (≥2: 78.7%) risk scores but a 
low HAS-BLED (0–2: 83.1%) score. Approximately two-thirds 
of the patients surveyed were using oral anticoagulants as an 
antithrombotic and one-third were using antiplatelet agents. 
The rate of persistence with initial treatment was approxi-
mately 86%. Bleeding was reported by 22.6% and 25.0% of 
patients at the 6th and 12th month, respectively. The propor-
tion of patients with an INR of 2.0–3.0 was 41.8% at baseline, 
65.7% at the 6th month, and 65.9% at the 12th month. The 
time in therapeutic range was 61.0% during 1 year of follow-
up. The median EuroQol 5-dimensional health questionnaire 
(EQ-5D) score of the patients at baseline and the 12th month 
was 0.827 and 0.778, respectively (p<0.001). The results indi-
cated that patient quality of life declined over time.
Conclusion: In atrial fibrillation, despite a high rate of persis-
tence with initial treatment, the outcomes of stroke prevention 
and patient quality of life are not at the desired level. National 
health policies should be developed and implemented to bet-
ter integrate international guidelines for the management of 
NVAF into clinical practice.
Amaç: Non-valvüler atriyum fibrilasyonunda (NVAF), hastala-
rın felç ve kanama riski ve tromboprofilaksi açısından değer-
lendirilmesi için klinik uygulama paternlerini belirlemek ve has-
taların tedavi sonuçlarını ve yaşam kalitelerini değerlendirmek.
Yöntemler: Türkiye genelinde 12 üçüncü basamak sağlık 
merkezinde yürütülen klinik sürveyans çalışma. Tedaviye yak-
laşım ve tedaviye uyum verileri NVAF’li hastalarda çalışma 
başlangıcında, 6. ve 12. aylarda kaydedildi.
Bulgular: Takip verileri, 210 hastanın (%57.1 erkek; ortala-
ma yaş, 64.86±12.87 yıl) 146’sında 6. ayda ve 140’ında 12. 
ayda telefon görüşmesiyle toplandı. Başlangıçta, hastaların 
çoğunda CHADS2 (≥2, %48.3) ve CHA2DS2-VASc (≥2, %78.7) 
risk skoru yüksekken HAS-BLED (0-2, %83.1) skoru düşük-
tü. Başlangıçta, 177 hasta (%84.3) herhangi bir AF tedavisi 
alıyordu. Antitrombotik tipini bildirenlerin yaklaşık üçte ikisi 
oral antikoagülan ve üçte biri antitrombosit ajan kullanıyor-
du. Başlangıç tedavisine devam oranı yaklaşık %86’ydı. Ka-
nama 6. ayda hastaların %22.6’sında ve 12. ayda %25’inde 
bildirildi. Hedef INR değeri 2–3 olan hastaların yüzdesi baş-
langıçta %41.8 iken, 6. ayda %65.7’ye ve 12. ayda %65.9’a 
yükseldi. Bir yıllık takipte, terapötik aralıkta geçen zamana 
hastaların %61.0’ında ulaşıldı. Hastaların medyan EQ-5D 
skorları başlangıçta 0.827 (0.145–1.000) ve 12. ayda 0.778 
(-0.040–1.000) idi (p<0.001). Sonuçlar, hasta yaşam kalitesi-
nin zamanla azaldığını gösterdi.
Sonuç: Atriyum fibrilasyonunda, tedavi ve başlangıç teda-
visine devam oranlarının yüksekliğine rağmen tromboprofi-
laksi sonuçları ve hastaların yaşam kaliteleri istenen düzey-
de değildi. Ulusal düzeyde sağlık politikaları geliştirilmelidir. 
NVAF’nin uluslararası kılavuzunu klinik uygulamaya daha 
iyi entegre etmek için ulusal sağlık politikaları geliştirilmeli 
ve uygulanmalıdır.
Received: October 14, 2016   Accepted: November 16, 2017
Correspondence: Dr. Ali Oto.  Hacettepe Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Turkey.
Tel: +90 312 - 440 20 21   e-mail: alioto@tksv.org
© 2018 Turkish Society of Cardiology
92
ABSTRACT ÖZET
ORIGINAL ARTICLE
Atrial fibrillation (AF) is the most common sus-tained arrhythmia, affecting 1% to 2% of the 
population.[1–3] The prevalence of AF increases with 
age, reaching 15% at 80 years.[3] Being a significant 
independent thromboembolic risk factor, AF causes a 
5-fold increase in the risk for stroke, and 1 in 5 of all 
strokes are attributed to AF.[4] Ischemic strokes asso-
ciated with AF are often fatal, and those patients who 
survive are frequently disabled and more likely to 
have a recurrence compared with patients with other 
causes of stroke.[5]
The appropriate thromboprophylaxis is central to 
the management of AF for the prevention of stroke. 
These treatment targets should be monitored closely 
from the first presentation, particularly in patients 
with newly diagnosed AF.
Treatment options in patients with AF should be 
individualized based on the risk (bleeding) versus 
benefit (prevention of stroke) of therapy, which is 
often difficult to assess.[6] Recent clinical guidelines 
suggest using several scoring tools, such as CHADS
2
 
(congestive heart failure, hypertension, age ≥75 years, 
diabetes mellitus, prior stroke or transient ischemic 
attack or thromboembolism) and CHA
2
DS
2
-VASc 
(congestive heart failure, hypertension, age ≥75 years, 
diabetes mellitus, prior stroke or transient ischemic 
attack or thromboembolism, vascular disease, age 65 
to 74 years, female) to evaluate the risk of stroke, or 
HAS-BLED (hypertension, abnormal renal or hepatic 
function, stroke, bleeding, labile international nor-
malized ratio [INR], age ≥65 years, drugs or alcohol) 
to evaluate the risk of bleeding.[4,6–8]
Thus, in the present study, the primary aim was to 
define the practice patterns for the assessment of stroke 
and bleeding risk and treatment to prevent throm-
boembolism in patients with nonvalvular AF (NVAF) 
in tertiary reference centers across the country, along 
with an assessment of the compliance of these prac-
tices with international AF management guidelines. 
In addition, outcomes of thromboprophylaxis and the 
quality of life of the patients were evaluated.
METHODS
Study design and population
This was a representative, prospective, observational 
study conducted from August 2012 through Novem-
ber 2013 at 10 tertiary healthcare centers across the 
country. The 
study did not in-
clude any inter-
vention in routine 
clinical practice. 
Consecutive pa-
tients who were 
18 years of age 
or older and di-
agnosed with 
NVAF (sustained 
arrhythmia last-
ing more than 30 
seconds on elec-
t rocard iogram 
[ECG] or ECG-
Holter moni-
toring) were in-
cluded. Patients 
with cognitive disorders, postoperative NVAF, or 
NVAF due to reversible causes (e.g., pneumonia or 
hyperthyroidism), those who had myocardial infarc-
tion or underwent any operation within the previous 
3 months, those who participated in another clinical 
trial in the previous 6 months, and pregnant or breast-
feeding females were excluded. Moreover, patients 
with severe aortic valve stenosis and severe tricuspid 
valve stenosis were also not included in the analysis.
Written, informed consent was obtained from 
each patient before initiation of the study procedures. 
The study was approved by the ethics committee of 
Baskent University Ankara Hospital and conducted 
in accordance with the latest version of the Helsinki 
Declaration.
Data collected in the study visits and the
measuring tools
As part of the study protocol, 3 visits were performed: 
a baseline clinical evaluation and a phone interview 
at the 6th and 12th month (phone visits). Thus, each 
patient was followed-up for 1 year in the study at 
6-month intervals.
In the baseline visit, the following data were 
recorded: sociodemographic characteristics, type of 
AF, cardiovascular risk factors, history of coronary 
artery disease, concomitant diseases and treatments, 
agents used for stroke prevention (oral anticoagu-
lant [warfarin, rivaroxaban, dabigatran, apixaban], 
Abbreviations:
AF	 Atrial	fibrillation
CHADS2	 Congestive	heart	failure,
	 hypertension,	age	≥75	years,
	 diabetes	mellitus,	prior	stroke
	 or	transient	ischemic	attack	or		
	 thromboembolism
CHA2DS2-VASc	 Congestive	heart	failure,
	 hypertension,	age	≥75	years,
	 diabetes	mellitus,	prior	stroke
	 or	transient	ischemic	attack	or		
	 thromboembolism,	vascular		
	 disease,	age	65	to	74	years,		
	 female
ECG	 Electrocardiogram
HAS-BLED	 Hypertension,	abnormal	renal
	 or	hepatic	function,	stroke,
	 bleeding,	labile	international		
	 normalized	ratio,	age	≥65	years,		
	 drugs	or	alcohol
INR	 International	normalized	ratio
NVAF	 Nonvalvular	AF
TTR	 Time	in	therapeutic	range
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or antiplatelet agent), physical findings, and echocar-
diographic findings. Thereafter, patients were clas-
sified into the risk groups according the CHADS
2
, 
CHA
2
DS
2
-VASc, and HAS-BLED scoring systems.
[8–10] At the baseline clinical visit, all of the patients 
were given a diary to record information on AF treat-
ment and INR results.
In follow-up phone visits, information on treatment 
course, side effects, persistence with initial treatment, 
INR results, hospital admissions, hospitalizations, and 
significant clinical events, such as stroke and bleeding, 
were collected. Patients were classified according to 
INR level of <2.0, 2.0–3.0, and ≥3.0. Time in therapeutic 
range (TTR) was calculated according to the Rosendaal 
method.[11] Percentage of time in the therapeutic INR 
(therapeutic TTR ≥60%) range of 2.0–3.0 and nonther-
apeutic INR range of <2 or ≥3 (nontherapeutic TTR 
<60%) were calculated for 1 year of follow-up.
The quality of life of the patients was assessed us-
ing the EuroQol 5-dimensional quality of life ques-
tionnaire (EQ-5D), for which validity and reliability 
have been performed.[12] The EQ-5D was completed 
at the baseline visit and in the telephone interview at 
the 12th month.
Statistical analysis
Data were analyzed using PASW Statistics for Win-
dows, Version 18 (SPSS Inc., Chicago, IL, USA). De-
scriptive statistics were expressed as numbers and per-
centages for categorical variables, and mean, standard 
deviation, median, and minimum and maximum values 
for numerical variables. Visual (histogram and prob-
ability graphs) and analytical (Kolmogorov-Smirnov/
Shapiro-Wilk tests) methods were used to test the nor-
mality of variables. If no more than 20% of the cells 
had expected frequencies less than 5, a chi-square test 
was used, and if not, Fisher’s exact test was used for 
2-group comparisons, and for multiple group compar-
isons, Fisher’s exact test was used. The McNemar test 
was used for paired group comparisons of dependent 
categorical variables. For non-normally distributed nu-
merical variables, the Mann-Whitney U test was used 
to compare 2 independent groups and the Kruskal-
Wallis test was used in the comparison of multiple in-
dependent groups. The Wilcoxon signed-rank test was 
used for paired group comparisons in the case of non-
normal distribution of dependent numeric variables. 
The level of statistical significance was set at p<0.05. 
RESULTS
Baseline characteristics
A total of 210 patients (120 males and 90 females; 129 
inpatients and 81 outpatients; mean age: 64.86±12.87 
years) with NVAF were included in the study. From 
the original 210 patients, follow-up data were col-
lected through phone interviews for 146 patients 
(58.2% female) at the 6th month and for 140 patients 
(60.0% female) at the 12th month. At the baseline eval-
uation, most patients had high CHADS
2
 (≥2: 48.3%) 
and CHA
2
DS
2
-VASc (≥2: 78.7%) risk scores, but low 
HAS-BLED scores (0–2: 83.1%). The mean baseline 
INR level of the patients was 2.15±0.88. In all, 41.8% 
(n=46) of the patients had an INR between 2.0 and 3.0. 
Heart valve regurgitation was recorded for 44.3% and 
36.4% of patients in the mitral and tricuspid valves, 
respectively. The baseline clinical characteristics of 
the patients are summarized in Table 1.
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Figure 1. (A) Agents used at baseline, and (B) change in 
agent with respect to risk groups. P=0.509 for CHADS2 risk 
groups, p=0.651 for HAS-BLED groups in Figure 1A. A p 
value could not be calculated for CHA2DS2-VASc in Figure 
1b due to the limited number of cases.
Turk Kardiyol Dern Ars94
anticoagulant used (p>0.05 for all, Table 2). The risk 
group according to CHADS
2
, CHA
2
DS
2
-VASc, and 
HAS-BLED score also had no significant effect on 
the choice of anticoagulant at baseline (oral antico-
agulant versus antiplatelet) (p>0.05 for all, Fig. 1a). 
In 34 patients (26.4%) who were on antiplatelet treat-
ment with CHA
2
DS
2
-VASc score of 2 or greater, the 
HAS-BLED score was calculated (data not shown).
The rate of persistence with the initial treatment 
was over 86% and no change in antithrombotic drug 
was recorded for approximately 21% of the patients 
in both 6-month and 12-month assessments (Table 3). 
Treatment and persistence with initial treatment
At baseline, 177 of 210 NVAF patients (84.3%) were 
not receiving any treatment for AF. At the 6th month, 
141 (96.6%) of 146 patients were receiving treat-
ment for AF, and at the 12th month, the figure was 136 
(97.1%) of 140 patients. Approximately two-thirds 
of the patients who reported the type of antithrom-
botic in use were taking oral anticoagulants, and the 
remaining one-third were using antiplatelet agents 
(Table 2). The type of AF, the presence of bleeding, 
stroke, cardiovascular events, and survival status of 
patients had no significant relationship to the type of 
Table 1. Baseline clinical and demographic characteristics of the patients (n=210)
Characteristics Characteristics
Age, years, mean±SD 64.86±12.87
Gender, n (%) 
 Male 120 (57.1)
 Female 90 (42.9)
Type of hospital care, n (%) 
 Out patient 81 (38.6)
 In patient 129 (61.4)
Type of atrial fibrillation, n (%) 
 Permanent 92 (43.8)
 Paroxysmal 69 (32.9)
 Persistent 49 (23.3)
Risk stratification, n (%) 
 CHADS2 
  0 35 (16.9)
  1 72 (34.8)
  ≥2 100 (48.3)
 CHA2DS2-VASc 
  0 25 (12.1)
  1 19 (9.2)
  ≥2 163 (78.7)
 HAS-BLED 
  0-2 172 (83.1)
  ≥3 35 (16.9)
International normalized ratio, n (%) 
 <2.0 47 (42.7)
 2.0-3.0 46 (41.8)
 ≥3.0 17 (15.5)
Echocardiography findings, n (%) 
 Mitral valve failure 124 (44.3)
  Mild 80 (64.5)
  Moderate 39 (31.5)
  Severe 5 (4.0)
 Tricuspid valve failure 102 (36.4)
  Mild 68 (66.7)
  Moderate 25 (24.5)
  Severe 9 (8.8)
 Aortic valve failure 37 (13.2)
  Mild 24 (66.7)
  Moderate 13 (33.3)
  Severe 0
 Mitral valve stenosis (mild) 9 (3.2)
  Mild 9 (100)
  Moderate –
  Severe –
 Aortic valve stenosis 5 (1.8)
  Mild 2 (40.0)
  Moderate 1 (20.0)
  Severe 2 (40.0)
 Tricuspid valve stenosis 3 (1.1)
  Mild 2 (66.7)
  Moderate 1 (33.3)
  Severe –
History of coronary artery disease, n (%) 
 Percutaneous coronary intervention 54 (26.6)
 Acute coronary syndrome 37 (21.0)
 Coronary bypass 24 (12.6)
SD: Standard deviation. The percentages were calculated based on the patients who provided the relevant information.
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Fifty-nine patients (77.6%) were using the same an-
tithrombotic at the baseline and at the 12th month, while 
8 patients (10.5%) changed from an oral anticoagu-
lant to an antiplatelet, and 9 patients (11.8%) changed 
from an antiplatelet to an oral anticoagulant during the 
12-month follow-up. The drug-change pattern revealed 
no association with CHADS
2
, CHA
2
DS
2
-VASc, and 
HAS-BLED risk stratification (Fig. 1b). The most com-
mon reason for the change in anticoagulant drug was 
non-therapeutic TTR (n=9, 34.6%, cumulatively), fol-
lowed by drug intolerance, bleeding, and other drug-re-
lated factors [12-month cumulative values: 6 (23.1%), 
6 (23.1%) and 5 (19.2%), respectively] (Table 3).
Clinical course of disease during 12-month follow-up
During the 12-month follow-up, 44.3% of NVAF pa-
tients went to the hospital for INR control and 80% 
for other reasons. Overall, 15 patients were hospital-
ized in the first 6 months, and 8 patients in the sec-
ond 6 months of the year of follow-up (Table 4). The 
most significant clinical event during the follow-up 
period was bleeding, which was reported by 22.6% 
and 25.0% of the patients in the 6- and 12-month 
phone interviews, respectively (Table 4). Only 8 pa-
tients reported major bleeding, including gastroin-
testinal, brain, lung, nasal, or urinary tract bleeding, 
at the 6-month visit, and 10 at the 12-month visit. 
Table 2. Treatment with oral anticoagulants versus antiplatelet agents with respect to 
time, type of atrial fibrillation, the presence of clinical events, and survival
  Oral anticoagulants Antiplatelet agents p
   n % n %
Follow-up time   
 Baseline 92 70.2 39 29.8 
 6th month 86 74.1 30 25.9 
 12th month 75 67.0 37 33.0 
Atrial fibrillation type   
 Persistent 21 63.6 12 36.4 0.630
 Permanent 52 72.2 20 27.8 
 Paroxysmal 19 73.1 7 26.9 
Bleeding   
 6th month
  Yes 19 76.0 6 24.0 0.343
  No 44 65.7 23 34.3 
 12th month
  Yes 22 75.9 7 24.1 0.519
  No 50 69.4 22 30.6 
Stroke   
 6th month 4 100 0 0 NA
 12th month 2 50 2 50 NA
Cardiovascular events
related to atrial fibrillation   
 6th month 4 80 1 20 NA
 12th month 1 33.3 2 66.7 NA
Survival   
 Survived 84 91.3 33 84.6 0.353
 Died 8 8.7 6 15.4 
The percentages were calculated based on the patients who provided the relevant information. NA: Not applicable as 
a result of the limited number of cases.
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(data not shown). Of the patients who used warfarin 
initially and at the 12th month, 48.6% had a bleeding 
complication. There was also no difference in the 
bleeding rate between the patients who used or started 
HAS-BLED category demonstrated no relationship 
to bleeding events. The HAS-BLED score was ≥3 
in 26.4% (n=14) of the patients with bleeding and in 
13.5% (n=10) of those without bleeding (p=0.067) 
Table 4. Clinical course of disease for 1 year of follow-up with phone interviews at 6-month intervals
  6-month follow-up 12-month follow-up p
  (n=146) (n=140)
  n % n %
Admission to the hospital for INR control 72 49.3 62 44.3 0.037
Admission to the hospital for reasons other than
INR control 76 52.1 112 80.0 <0.001
Hospitalization  15 10.2 8 5.7 
Change in physician 52 35.6 73 52.1 0.002
Clinical events   
 Bleeding* 33 22.6 35 25.0 
 Stroke 6 4.1 5 3.6 
 Others 19 13 16 11.4 
 Cardiovascular events related to atrial fibrillation 9 6.2 7 5 
 Cardiovascular events not related to atrial fibrillation 12 8.2 5 3.6 
 None 68 46.6 75 53.6 
Death 15 9.3 5 3.4 
INR: International normalized ratio. *Brain bleeding, urinary tract bleeding, bowel bleeding, gingival bleeding, nasal bleeding, bleeding due to simple or seri-
ous trauma etc., except for menstrual bleeding. At 6-month and 12-month follow-up interviews, 8 and 10 patients reported major bleeding, respectively. The 
percentages were calculated based on the patients who provided the relevant information.
Table 3. Persistence with initial treatment and changes during treatment
  6-month follow-up 12-month follow-up p
  (n=146) (n=140)
  n % n %
Drug continuance 122 86.5 118 86.8 0.727
Change in anticoagulant drug 26 21.3 25 21.4 0.815
Change in the dosage of anticoagulant agent 41 33.6 42 36.8 0.742
Reasons for the change in anticoagulant drug   
 Outside the therapeutic INR range (TTR) 4 22.2 7 43.8 
 Intolerance 3 16.7 4 25.0 
 Bleeding 3 16.7 3 18.8 
 Drug-related factors other than intolerance
 (i.e., ineffectiveness, price etc.) 8 44.4 2 12.5
Addition of a new drug to the current anticoagulant
treatment 61 50.0 88 75.2 <0.001
INR: International normalized ratio; TTR: Time in therapeutic range. The percentages were calculated based on the patients who provided the relevant 
information.
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ity and warfarin treatment: 7 of 92 patients (7.6%) 
who used warfarin at baseline died, while 13 of 118 
(11.0%) who did not use warfarin at baseline died dur-
ing the follow-up period (p=0.404) (data not shown). 
The mortality rate was not significantly higher in the 
patients who were not using warfarin initially and 
to use warfarin and those who did not use or discon-
tinued warfarin (42.9% vs. 43.9%; p=0.917) (data not 
shown).
Around half of the patients had no clinical event. 
Twenty patients died during the 12-month follow-up 
(Table 4). There was no correlation between mortal-
Table 5. INR of patients with respect to evaluation time, presence of clinical event, bleeding, 
stroke, and hospitalization
 INR <2.0 INR 2.0–3.0 INR ≥3.0 p
   n % n % n %
Total    
 6th month 7 20.0 23 65.7 5 14.3
 12th month 11 25.0 29 65.9 4 9.1
Clinical event    
 6th month
  Yes 3 13.6 15 68.2 4 18.2 0.403
  No 4 30.8 8 61.5 1 7.7 
 12th month
  Yes 6 22.2 18 66.7 3 11.1 NA
  No 5 29.4 11 64.7 1 5.9 
Bleeding     
 6th month
  Yes 2 18.2 7 63.6 2 18.2 1.000
  No 5 20.8 16 66.7 3 12.5 
 12th month
  Yes 2 14.3 9 64.3 3 21.4 NA
  No 9 30.0 20 66.7 1 3.3 
Stroke     
 6th month
  Yes 1 33.3 2 66.7 0 0.0 NA
  No 6 18.8 21 65.6 5 15.6 
 12th month
  Yes 2 66.7 1 33.3 0 0.0 
  No 9 22.0 28 68.3 4 9.8 
Hospitalization     
 6th month
  Yes 0 0.0 6 85.7 1 14.3 NA
  No 4 26.7 8 53.3 3 20.0 
 12th month
  Yes 4 23.5 10 58.8 3 17.6 NA
  No 6 24.0 18 72.0 1 4.0 
INR: International normalized ratio. The percentages were calculated based on the patients who provided the relevant 
information. The analysis was performed using the data of patients with laboratory analysis results from within the previous 
2 months. NA: Not applicable as a result of the limited number of cases.
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Table 6. Rate of therapeutic or non-therapeutic time in therapeutic range for 1 year of follow-up
  Therapeutic TTR Non-Therapeutic TTR p
Total 36 (61.0) 23 (39.0) 
Bleeding   
 Yes 17 (65.4) 9 (34.6) 0.569
 No 15 (57.7) 11 (42.3) 
Stroke   
 Yes 2 (40.0) 3 (60.0) 0.361
 No 30 (63.8) 17 (36.2) 
Clinical event   
 Yes 25 (59.5) 17 (40.5) 0.626
 No 10 (66.7) 5 (33.3) 
Drug groups 30 (66.7) 15 (33.3) NA
 Oral anticoagulants*   
 Antiplatelet agents 1 (33.3) 2 (66.7) 
Cardiovascular events related
to atrial fibrillation 2 (66.7) 1 (33.3)
TTR: Time in therapeutic range. The percentages were calculated based on the patients who provided the relevant information. 
Therapeutic TTR (≥60%) corresponds to normal INR level (INR=2-3); Non-therapeutic TTR (<60%) corresponds to INR <2 or 
INR≥3. *Of the patients using oral anticoagulants, all were taking warfarin. INR: International normalized ratio; NA, not applicable 
as a result of the limited number of cases.
over time. The EQ-5D score did not indicate a sig-
nificant difference with respect to the type of AF, 
drug group, or presence of bleeding at baseline and 
the 12th month (Table 7). However, the quality of life 
of the patients who used oral anticoagulants signifi-
cantly worsened over time. The EQ-5D scores of pa-
tients who used antiplatelet agents also deteriorated 
over time without a significant difference (Table 7). 
While the presence of bleeding or any clinical event 
had no effect on EQ-5D score at baseline (p=0.873 
and p=0.402), patients with a bleeding complication 
or a clinical event had significantly lower scores than 
those without at the 12th month (p=0.018 and p=0.011, 
respectively). The quality of life of the patients with 
bleeding became poorer over time. The EQ-5D score 
of patients who were treated with an oral anticoag-
ulant during the 12-month follow-up also decreased 
significantly (p=0.006; Table 7).
DISCUSSION
Drug treatment in AF aims to reduce the risk of AF-
related severe thromboembolic events[7,13] and this is 
basically managed with antithrombotic therapy (an-
ticoagulant). However, such therapy is associated 
then changed drug (11/92, 12.0%) than those who 
were using warfarin at baseline and then changed 
drug (9/118, 7.6%) (p=0.289) (data are not shown). 
Change in international normalized ratio during 
follow-up
The percentage of patients with the target INR (2.0 to 
3.0), which was 41.8% at baseline, increased to 65.7% 
at the 6th month and 65.9% at the 12th month (Table 
5). The presence of a clinical event, bleeding, stroke, 
or hospitalization was not significantly related to the 
ratio of patients with the target INR (p>0.05 for all, 
Table 5). The therapeutic TTR was 61.0% during the 
year of follow-up. The mean TTR was 65.9±32.6%. 
The presence of bleeding, stroke, or clinical event did 
not affect the therapeutic TTR (p>0.05 for all, Table 
6). The relationship between anticoagulant drug group 
and therapeutic TTR could not be evaluated due to the 
limited number of cases (Table 6).
Quality of life
The median EQ-5D score of the patients at baseline 
and at the 12th month was 0.827 (range: 0.145–1.000) 
and 0.778 (range: -0.040–1.000) (p<0.001), respec-
tively. Thus, the quality of life of patients declined 
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Table 7. EuroQol 5-dimensional questionnaire scores of the patients at baseline and 12th month
  Baseline 12th month p
Total 0.827 (0.145–1.000) 0.778 (-0.040–1.000) <0.001
Type of atrial fibrillation   
 Persistent 0.843 (0.543–1.000) 0.770 (0.193–1.000) <0.001
 Permanent 0.805 (0.145–1.000) 0.681 (-0.040–1.000) <0.001
 Paroxysmal 0.833 (0.333–1.000) 0.827 (0.077–1.000) 0.040
 p 0.117 0.043 
Drug groups   
 Oral anticoagulants 0.827 (0.333–1.000) 0.728 (0.165–1.000) 0.003
 Antiplatelet agents 0.705 (0.145–1.000) 0.699 (-0.040–1.000) 0.333
 p 0.219 0.815 
Bleeding   
 Yes 0.833 (0.597–1.000) 0.689 (-0.040–1.000) <0.001
 No 0.835 (0.165–1.000) 0.800 (0.165–1.000) 0.001
 p 0.873 0.018 
Clinical event   
 Yes 0.827 (0.165–1.000) 0.742 (-0.040–1.000) <0.001
 No 0.844 (0.543–1.000) 0.800 (0.235–1.000) 0.045
 p 0.402 0.011 
Drug usage pattern throughout the study   
 Oral anticoagulant 0.816 (0.165–1.000) 0.755 (0.165–1.000) 0.006
 Antiplatelet agents 0.757 (0.597–1.000) 0.800 (-0.040–1.000) NA
 Oral anticoagulant →Antiplatelet 1.000 (0.597–1.000) 0.742 (0.397–1.000) NA
 Antiplatelet→Oral anticoagulant 0.794 (0.308–1.000) 0.499 (0.165–1.000) NA
EuroQol 5-dimensional questionnaire (EQ-5D) scores of the patients who were followed-up in both the 6th and 12th months were analyzed. For bleeding and 
clinical event, cumulative data were used. For analysis of EQ-5D scores in drug groups, only the data of the patients using the same drug throughout the 
study were included. NA: Not applicable as a result of the limited number of cases.
strated for these regimens.[20,21] Therefore, oral antico-
agulant use is currently the gold-standard antithrom-
botic regimen for NVAF. Although international 
guidelines have been developed for risk assessment 
and stroke prevention of AF, the implementation of 
the guidelines has not been fully realized and real-
life practice may include variations in different health 
care settings.
In this study conducted at tertiary reference cen-
ters, only two-thirds of the patients were taking oral 
anticoagulants and the remaining one-third were on 
antiplatelet agents. Similarly, in the RAMSES (Real-
life Multicentre Survey Evaluating Stroke Prevention 
Strategies) study,[22] the largest study in Turkey eval-
uating stroke prevention strategies in NVAF patients 
(n=6273), 72% and 32% of the study population were 
on oral anticoagulants and antiplatelet agents, respec-
with an increased risk of bleeding; thus, both the 
benefit and the risk should be taken into account in 
AF treatment planning. Many clinical trials [SPAF 
(Stroke Prevention in Atrial Fibrillation), AFASAK 
(Atrial Fibrillation, Aspirin, Anticoagulation Ther-
apy Study), BAATAF (Boston Area Anticoagulation 
Trial in Atrial Fibrillation), SPINAF (Stroke Preven-
tion in Nonrheumatic Atrial Fibrillation), and CAFA 
(Canadian Atrial Fibrillation Anticoagulation)] have 
demonstrated that warfarin significantly reduces the 
incidence of stroke compared with a placebo in pa-
tients with AF at moderate to high risk of thromboem-
bolic events (CHA
2
DS
2
-VASc score ≥2).[14–19] The risk 
of serious bleeding, however, doubles with warfarin 
anticoagulation. In addition to oral anticoagulants, 
various antiplatelet regimens have been studied, but 
no clinical benefit over warfarin has been demon-
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the WARFARIN TR study,[25] the bleeding rate within 
a year was reported to be 20.1%.
One of the limitations of the present study was 
the inclusion of patients only from tertiary healthcare 
centers; patients may have been admitted for complex 
procedures. In addition, potential changes to the reim-
bursement system of the Social Security Institute may 
have resulted in changes in clinical practice after the 
present study. 
In conclusion, oral anticoagulants are underused 
and antiplatelets are prescribed for a significant num-
ber of patients, even at tertiary reference centers. De-
spite the high probability of treatment and persistence 
with initial treatment, the outcome of thrombopro-
phylaxis as well as patient quality of life were not at 
the desired level. Thus, we suggest that health poli-
cies at national level should be developed and imple-
mented to better integrate international guidelines for 
the management of NVAF into clinical practice.
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